Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson buys women's health-focused Uteron for up to $305m as it adopts Actavis name

This article was originally published in Scrip

Executive Summary

On the eve of Watson Pharmaceuticals' transition to a new name in honor of the company's $5.6 billion acquisition of global generics competitor Actavis in 2012, the US firm has announced a purchase worth up to $305 million that's meant to fill its brand-name drug pipeline and increase the company's presence in the women's health market.

You may also be interested in...

Nonprofit Medicines360 Provides Affordable Contraception, Women’s Health

Emerging Company Profile: Medicines360 and partner Allergan launched the IUD Liletta in 2015, so now the nonprofit pharmaceutical company is looking for additional contraceptives and women’s health products.

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer

Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts